Being certain about uncertainties: a robust evaluation method for high-dose-rate prostate brachytherapy treatment...

In high-dose-rate (HDR) prostate brachytherapy the combined effect of uncertainties cause a range of possible dose distributions deviating from the nominal plan, and which are not considered during treatment plan evaluation. This could lead to dosimetric misses for critical structures and overdosing of organs at risk. A robust evaluation method to assess the combination of uncertainties during plan evaluation is presented and demonstrated on one HDR prostate ultrasound treatment plan retrospectively. A range of uncertainty scenarios are simulated by changing six parameters in the nominal plan and calculating the corresponding dose distribution. Two methods are employed to change the parameters, a probabilistic approach using random number sampling to evaluate the likelihood of variation in dose distributions, and a combination of the most extreme possible values to access the worst-case dosimetric outcomes. One thousand probabilistic scenarios were run on the single treatment plan with 43.2% of scenarios passing seven of the eight clinical objectives. The prostate D₉₀ had a standard deviation of 4.4%, with the worst case decreasing the dose by up to 27.2%. The urethra D₁₀ was up to 29.3% higher than planned in the worst case. All DVH metrics in the probabilistic scenarios were found to be within acceptable clinical constraints for the plan under statistical tests for significance. The clinical significance of the results from the robust evaluation method presented on any individual treatment plan needs to be compared in the context of a historical data set that contains patient outcomes with robustness analysis data to ascertain a baseline acceptance.